Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542

Japan

Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

Press Release

Worldwide Medtech Sales Forecast to Reach $455 Billion by 2018

Forecast data show that the future of medtech is solid, despite disappointing year

AdvaMed 2013

Download PDF

LONDON, BOSTON, TOKYO (September 23, 2013) — The medical device and diagnostics market is set to grow at  4.5 percent per year (CAGR) between 2012 and 2018, totalling $455 billion in 2018, according to the newly-released EvaluateMedTech World Preview 2013, Outlook to 2018: The Future of Medtech report from market intelligence firm Evaluate Ltd. The report predicts that in vitro diagnostics (IVD) will retain its position as the world’s largest medtech segment in 2018, with global sales totaling $58.8 billion, followed by cardiology and then diagnostic imaging. 

The second edition EvaluateMedTech World Preview report provides top-level insight from the world’s financial markets into the expected performance of the medical device and diagnostic industry between now and 2018.  The report was released today at AdvaMed 2013 in Washington, D.C., and is available as a free download at www.evaluategroup.com/MedTechWP2013.

While the IVD category holds the greatest market share, neurology has set the pace as the fastest-growing of the top 15 device areas, with an annual growth rate of 6.9 percent between 2012 and 2018. Meanwhile, the diabetic care and orthopedics categories are expected to be the slowest growing of the top 15 device areas, expanding by only 3.4 percent per year (CAGR) between 2012 and 2018.

“Despite the medtech industry having a tough first half of 2013, with M&A deal values and PMA approvals declining, consensus forecasts predict healthy growth in the months and years ahead resulting in a $455 billion market by 2018,” said Ian Strickland, Product Manager of EvaluateMedtech and author of the report. “Within the industry the leading segment of in vitro diagnostics continues to grow more strongly than the medtech market as a whole, thanks to advances in molecular diagnostics and drugs becoming increasingly linked to diagnostic tests.”

In addition to forecasting medtech segment growth and overall worldwide sales, the report also examines key topics including R&D spending, company performance by segment, FDA approvals, M&A deal values and venture financing.  Among the key findings:

  • Sales growth in the medtech industry is set to outperform the prescription drug market between 2012 and 2018, with a CAGR of 4.5 percent compared with pharma’s more modest 3.8 percent.
  • Of the top medtech companies, Johnson & Johnson is expected to take home the market-leading spot in 2018 with $33.4 billion in worldwide medtech sales.
  • Global medtech R&D spending is set to grow by 3.9 percent per year to reach $26.7 billion by 2018; Siemens is seen to be the top R&D spender with its investment in new medtech programs forecast to reach $2 billion by 2018.
  • First-time premarket approvals (PMAs) decreased 5 percent to 41 in 2012. So far the FDA has approved 14 new PMAs in 2013 to the end of August, representing a 42 percent decline over the same period last year.
  • M&A deal value fell by a startling 79 percent in the first half of 2013 compared with the same period in 2012. Deal counts dropped 15 percent.
  • Venture financing fell 14 percent in 2012 to $3.8 billion but expanded 6 percent in the first half of 2013, reaching $2.5 billion.

For more information on the 2013 Edition of the EvaluateMedTech World Preview, visit Evaluate Booth 414 at AdvaMed. The executive summary and full report are available for download at www.evaluategroup.com/MedTechWP2013.

About Evaluate Ltd

Evaluate is the trusted source for high quality commercial market intelligence and exclusive consensus sales forecasts to 2018.  Our services are EvaluatePharma, EvaluateMedTech and EvaluateClinicalTrials. Our award-winning editorial arm, EP Vantage, leverages our market intelligence and analysis to provide daily opinion and insights. Evaluate’s services give you the insights you need to ask the right questions and get the right answers. That’s intelligence you can act on. For more information visit: www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial, @epvantage.

Back to Press Releases